SP066
LONG- TERM RAMIPROT: A RENAL FUNCTION FOLLOW- UP STUDY Free

INTRODUCTION AND AIMS: CKD progression is highly influenced by proteinuria. Major mechanisms of renal damage progression due to proteinuria are sustained by the pleiotropic effects of the Renin Angiotensin Aldosterone system (RAAS) up-regulation. In a previous study (RamiPROT) our research group compared the antiproteinuric efficacy of different doses of Ramipril given in a single daily administration (SDA) or divided in two daily administrations (TDA) in patients affected by mild proteinuric nephropathy. The best antiproteinuric performance of Ramipril was found when the drug was administered at high dose and in TDA. We present the preliminary data of Long Term RamiPROT protocol, in which we supposed that TDA Ramipril 10 mg/day, compared to SDA Ramipril 10 mg/day, is associated with a slower CKD progression.

METHODS: Long Term RamiPROT is an ongoing monocentric, prospective, randomized study in which all 36 patients who previously participated in RamiPROT study were randomized in two arms: SDA Ramipril 10 mg/day and TDA Ramipril 10 mg (Ramipril 5 mg x 2/day). CKD-EPI eGFR, 24-h proteinuria, blood pressure were evaluated at 1, 3, 6, 12, 24-36-month follow-up.

RESULTS: At two-year follow-up, 24 h proteinuria remained significantly lower and, of note, eGFR decline rate was significantly lower in TDA Ramipril 10 mg/day group. (Figure 1).

CONCLUSIONS: These preliminary data suggest that TDA Ramipril 10 mg/day could be more effective than SDA Ramipril 10 mg/day in slowing CKD progression.